GlassScriptPhysician profile
Mayurkumar M Gohel
NPI 1245593490
$2,023.89
in general payments reported to CMS, 2019-2025
20 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $381 · 2024: $1,004 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $38.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.24 |
| Education | $38.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $353.94 | 2023-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $293.82 | 2023-2025 | Farxiga, Lokelma |
| Stryker Corporation | $168.50 | 2025 | Venacore Thrombectomy Catheter |
| Otsuka America Pharmaceutical, INC. | $159.74 | 2023-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $122.45 | 2023-2025 | Velphoro, Velphoro |
| Inari Medical, INC. | $120.87 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.64 | 2023-2024 | Jardiance |
| Travere Therapeutics, INC. | $96.95 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $96.93 | 2023-2025 | |
| Vifor Pharma, INC. | $80.98 | 2023-2024 | Veltassa |
| Nxstage Medical, INC. | $62.50 | 2025 | Liberty Select Cycler, Nxstage System One |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.07 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.97 | 2024 | |
| Glaxosmithkline, LLC. | $56.75 | 2023-2024 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $52.70 | 2024-2025 | Vafseo, Auryxia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.88 | 2023-2024 | Rybelsus, Ozempic |
| Calliditas Therapeutics US INC. | $29.74 | 2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $28.19 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $27.48 | 2024 | Acthar |
| Ardelyx, INC. | $16.79 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayurkumar Gohel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.